glp-1 substance use disorder GLP1 receptor agonists are supported by preclinical and observational evidence for reducing addictive behaviors, particularly alcohol and nicotine use. Initial randomized clinical trials indicate possible reductions in craving and intake, though Transformation 2.0: The GLP-1 RAs

Yang L, Chen L, Li D, Xu H, Chen J, Min X, He M, Wu T, Zhong J, Yang H

With practice, restaurant ordering on GLP-1s becomes second nature

And we know in Massachusetts we are very proud of MassHealth, that started covering these drugs, weight loss drugs, since January 2024

Similarly, in the STEP-HFpEF DM trial, which included 616 obese HFpEF patients with comorbid T2DM, once-weekly semaglutide 2.4 mg improved the KCCQ-CSS by 13.7 points versus 6.4 points with placebo at 52 weeks [103]

Though its a good idea to pull back on sugars and refined carbs, your diet doesnt need to be restrictive

Lets keep fighting for patients.